drugset

drugset / Trial / NCT07011706

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706 ↗

Phase 2 Active not recruiting 110 enrolled Aclaris Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Timeline

Start: 2025-05-30
Primary completion: 2026-08
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ATI-045	Unknown	—	—

Indications